65 Patienten (34 Frauen, 31 Manner) mit akuter myeloischer Leukämie erhielten eine Induktionstherapie bestehend aus Cytarabin (100 mg/m2 kontinuierlich i.v. Tage 1–7) und Daunorubicin (45 mg/m2 i.v. Tage 1–3). Die Patienten waren unvorbehandelt, das Alter lag zwischen 15 und 71 (Median 43) Jahren. Die supportive Behandlung bestand aus Breitspektrumantibiotika für fieberhafte Infekte bei Granulozytopenie und Substitution von Erythro- und Thrombozyten. Die Rate der Vollremissionen betrug 55,3%. Im Mittel wurden 1,5 Therapiezyklen und 41 Tage benötigt, urn eine Vollremission zu erreichen. Geschlecht und Alter schienen die Remissionsrate nicht zu beeinflussen. Zur Remissionserhaltung wurden in zyklischen Intervallen Cytarabin (200 mg/m2 i.v. in 2 Dosen Tage 1–5) und alternierend eine der Substanzen: 6-Thioguanin (200 mg/m2 p.o. in 2 Dosen Tage 1–5), Cyclophosphamid (800 mg/m2 i.v. Tag 1), CCNU (100 mg p.o. Tag 1) oder Daunorubicin (45 mg/m2 i.v. Tage 1–2) gegeben. Eine mediane Remissionsdauer von 44 Wochen wurde erreicht. Die mediane Überlebenszeit betrug für alle Patienten 31 Wochen, für Therapieansprecher 74 und für Therapieversager 8 Wochen.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.